-
DE
Progeria is an extremely rare genetic disorder in which children age rapidly. Life expectancy is severely reduced.
Progeria is an extremely rare genetic disorder in which children age rapidly. Life expectancy is severely reduced.
Progeria, medically known as Hutchinson-Gilford Progeria Syndrome (HGPS), is an extremely rare and severe genetic disorder in which affected children undergo a dramatically accelerated aging process. The term derives from Greek: pro meaning early and geras meaning old age. It is estimated that only 350 to 400 children worldwide are living with this condition at any given time.
Progeria is caused by a point mutation in the LMNA gene, located on chromosome 1. This gene encodes for the protein Lamin A, which plays a critical role in maintaining the structural integrity of the cell nucleus. The mutation produces a defective version of this protein called Progerin. Progerin accumulates in the nuclear membrane, destabilizes cell nuclei, and triggers premature cell death. The mutation typically occurs spontaneously (de novo) and is not inherited from parents. The risk of the condition is independent of sex, ethnicity, or geographic origin.
Children with Progeria appear healthy at birth. However, within the first year of life, characteristic features begin to appear:
The intellectual development of affected children is generally not impaired.
Progeria is diagnosed primarily through clinical assessment based on the characteristic physical features. Diagnosis is confirmed by a genetic test identifying the specific mutation in the LMNA gene. Early diagnosis is essential to initiate appropriate treatment in a timely manner.
Other rare progeria-like syndromes, such as Werner Syndrome (which occurs in adulthood) or Cockayne Syndrome, must be excluded.
There is currently no cure for Progeria. Treatment focuses on extending life expectancy and improving quality of life.
In 2020, Lonafarnib (brand name: Zokinvy) was approved by the U.S. Food and Drug Administration (FDA) as the first drug specifically indicated for Progeria. Lonafarnib is a farnesyltransferase inhibitor that prevents Progerin from attaching to the nuclear membrane, thereby slowing down cell death. Clinical studies demonstrated that Lonafarnib can extend the life expectancy of patients by an average of approximately 2.5 years.
Life expectancy in Progeria is severely reduced. The average age at death is approximately 13 to 14 years. The most common cause of death is a heart attack or stroke, resulting from severe atherosclerosis. The introduction of Lonafarnib has modestly improved life expectancy in recent years.
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, lactic acid bacteria, and Lactoferrin CLN®
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, lactic acid bacteria, and Lactoferrin CLN®
For your universal protection
As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
For your iron balance
Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.